bupropion has been researched along with ticlopidine in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (42.86) | 29.6817 |
2010's | 8 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Dalvie, D; Halpert, JR; Shah, MB; Talakad, JC; Walker, GS; Xiang, C | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Eichelbaum, M; Heinkele, G; Mürdter, TE; Pleiss, J; Richter, T; Schwab, M; Tatzel, S; Zanger, UM | 1 |
Juntunen, T; Nieminen, R; Pelkonen, O; Raunio, H; Taavitsainen, P; Turpeinen, M | 1 |
Jalonen, J; Laine, K; Pelkonen, O; Tolonen, A; Turpeinen, M; Uusitalo, J | 1 |
Astuccio, AV; Obach, RS; Walsky, RL | 1 |
Bateman, ND; Buchanan, D; Clark, RC; Cuthbert, M; Kerr, S; Maxwell, SR; Steinke, D; Webb, DJ | 1 |
Hassan, HE; Moeller, BM; Molnari, JC; Myers, AL | 1 |
Desta, Z; Guo, Y; Ogburn, ET; Xu, C | 1 |
1 review(s) available for bupropion and ticlopidine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for bupropion and ticlopidine
Article | Year |
---|---|
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Bupropion; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2B6; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Humans; Hydroxylation; Male; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Ticlopidine | 2005 |
12 other study(ies) available for bupropion and ticlopidine
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Bupropion; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Enzyme Inhibitors; Humans; Kinetics; Models, Molecular; Molecular Structure; Oxidation-Reduction; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Ticlopidine | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Topics: Aryl Hydrocarbon Hydroxylases; Bupropion; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Humans; Hydroxylation; In Vitro Techniques; Microsomes, Liver; Oxidoreductases, N-Demethylating; Structure-Activity Relationship; Thiotepa; Ticlopidine | 2004 |
Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.
Topics: Algorithms; Alkynes; Antidepressive Agents, Second-Generation; Antifungal Agents; Area Under Curve; Benzoxazines; Bupropion; Clopidogrel; Clotrimazole; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Itraconazole; Kinetics; Microsomes, Liver; Molecular Structure; Oxazines; Platelet Aggregation Inhibitors; Raloxifene Hydrochloride; Reverse Transcriptase Inhibitors; Selective Estrogen Receptor Modulators; Selective Serotonin Reuptake Inhibitors; Sertraline; Ticlopidine; Xenobiotics | 2006 |
The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Bupropion; Capecitabine; Citalopram; Clopidogrel; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Monitoring; Drug Prescriptions; Drug Utilization Review; Fluorouracil; Humans; Lactones; Meningococcal Vaccines; Platelet Aggregation Inhibitors; Primary Health Care; Scotland; Sulfones; Ticlopidine; Time Factors | 2007 |
Drug interaction study between bupropion and ticlopidine in male CF-1 mice.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Brain; Bupropion; Cytochrome P-450 CYP2B6; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Hydroxylation; Male; Mice; Mice, Inbred Strains; Oxidoreductases, N-Demethylating; Ticlopidine | 2011 |
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Topics: Alkynes; Alleles; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Bupropion; Catalysis; Clopidogrel; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochromes b5; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyrimidines; Substrate Specificity; Ticlopidine; Triazoles; Voriconazole | 2012 |